Intellipharmaceutics International


Stock Update (NASDAQ:IPCI): IntelliPharmaCeutics Intl Inc (USA) Announces Agreement to Acquire Real Property and Status of 5mg Strength of its Generic Focalin XR(R)

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid …

Stock Update (NASDAQ:IPCI): IntelliPharmaCeutics Intl Inc (USA) Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program Due To Positive Feedback from FDA

IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid …

Stock Update (NASDAQ:IPCI): Intellipharmaceutics Intl Inc (USA) Announces First Quarter 2015 Results

Intellipharmaceutics Intl Inc (USA) (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid …

Stock Update (NASDAQ:IPCI): Intellipharmaceutics Reports Positive Topline Data Results from a Series of Phase I Clinical Trials of its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, and files an IND for Rexista(TM) Oxycodone XR

Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic …

Stock Update (NASDAQ:IPCI): Intellipharmaceutics Announces 2014 Year End Results With a 48% Reduction in Operating Loss

Intellipharmaceutics International Inc. (Nasdaq:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid …

Maxim Maintains Buy On Intellipharmaceutics Following Regabatatin XR Update

In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Intellipharmaceutics International (NASDAQ:IPCI) with a $7 price target, …

Brean Capital Reiterates Buy On Intellipharmaceutics Following FY3Q14 Results

In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Intellipharmaceutics International (NASDAQ:IPCI) with a price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts